Noninvasive prenatal testing (NIPT) performed with massively parallel sequencing of cell-free DNA (cfDNA testing) in maternal plasma came into use in clinical prenatal care in the US in late 2011. As a result of multiple clinical validation studies, a variety of methods/technologies have evolved with specific strengths and weaknesses. As a result, clinicians need to understand the different methodologies and know how to implement them into their clinical practice. Primary questions involve the use of NIPT as a primary or secondary screen, which patients to offer this testing to, how conventional measures, such as nuchal translucency screening and anatomy ultrasound should be used in conjunction with NIPT, and what pre- and post-test counseling is necessary. In this 45-minute webinar, Joe Leigh Simpson, MD, Senior Vice President for Research and Global Programs at the March of Dimes Foundation, will provide an overview of various approaches and discuss his recommendations on how to best implement this major advance in prenatal screening.